Experimental Cellular Pathology

实验细胞病理学核心旨在为研究人员提供集中的病理服务，包括免疫组织化学(IHC)和流式细胞术(FCM)程序，以支持所有四个项目。这一资源结合了UAMS病理学系和骨髓瘤研究与治疗研究所的专业知识和设施。将这些核心服务集中起来，将不再需要每个调查员在自己的实验室建立这些服务，而且还能提供统一的程序和有效利用材料和国会设备的额外好处。核心将涉及以下具体目标：具体目标1：为每个P01项目的调查人员提供病理学服务。具体地说，这将包括IHC和激光捕获显微切割(LCM)。IHC服务将在项目1提供的患者样本上进行，并用于支持项目1、2和3以及项目2和4中的活体动物模型研究。组织切片IHC的主要优势是组织的形态保持完好，形态和免疫学特征可以整合在一起，以便对骨髓结构进行显微解剖分析。LCM服务将在项目1和项目4中发挥重要作用，在这些项目中，研究将检查局灶性和间质性疾病模式以及骨髓微环境。具体目标2：构建组织芯片(TIVIA)。核心的一个核心方面将是使用从新患者以及项目1中登记的治疗方案中的患者获得的材料来构建TMA。基因表达图谱和蛋白质组学在POI中发挥核心作用，通过使用TMA等材料，核心E将发挥重要作用，协助项目1与核心C一起验证与通过这些技术确定的肿瘤细胞/骨髓微环境有关的关键基因和蛋白质。具体目标3：提供流式细胞仪服务，以验证最小残留疾病监测的新标记物，并用于表征和鉴定具有不同遗传和生物学特性的骨髓瘤亚群。相对较新的恶性浆细胞异常免疫表型的鉴定和独特的能力，即使是微小的细胞亚群的鉴定和特征使FCM成为一种理想的技术，以实现项目1中描述的目标。FCM也将用于项目2中将开发的扩增的NK细胞制剂的免疫表型表征。

The Experimental Cellular Pathology Core is designed to provide investigators with centralized pathologic services, including immunohistochemical (IHC) and flow cytometric (FCM) procedures in support of all four projects. This resource combines the expertise and facilities of the UAMS Department of Pathology with those of the Myeloma Institute for Research and Therapy. Centralizing these core services will avoid the need for each investigator to establish them in their own laboratories and will have the added benefit of providing for uniformity of procedures and efficient use of materials and capitol equipment. The core will address the following specific aims: Specific Aim 1: Provide pathology services to investigators in each P01 project. Specifically, this will include IHC and laser capture microdissection (LCM). IHC services will be performed on patient samples provided by Project 1 and utilized in support of Projects 1, 2 and 3 as well as on in vivo animal model studies in Projects 2 and 4. A major advantage of tissue section IHC is that the topography of the tissue remains intact and morphologic and immunologic features can be integrated to allow for microanatomic analysis of the bone marrow architecture. LCM services will be instrumental in Projects 1 and 4 where studies will examine focal and interstitial disease patterns as well as the marrow microenvironment. Specific Aim 2: Construct tissue microarrays (TIVIAs). A central aspect of the core will be the construction of TMAs using material derived from new patients as well as patients enrolled onto treatment protocols in Project 1. Gene expression profiling and proteomics play central roles in the POI and by using materials such as the TMAs, Core E will provide an important function by assisting Project 1, in conjunction with Core C, in the validation of key genes and proteins relating to the tumor cell/bone marrow microenvironment identified through these technologies. Specific Aim 3: Provide flow cytometry services to validate novel markers of minimal residual disease monitoring, and for characterization and identification of myeloma subpopulations with distinct genetic and biologic properties. The relatively recent identification of aberrant immunophenotypes in malignant plasma cells and the unique ability of to identify and characterize even minor cellular subpopulations makes FCM an ideal technology to accomplish the goals delineated in Project 1. FCM will also be useful for the immunophenotypic characterization of the expanded NK cell preparations that will be developed in Project 2.